These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1852 related items for PubMed ID: 16845641

  • 1. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [Abstract] [Full Text] [Related]

  • 2. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 3. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME.
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [Abstract] [Full Text] [Related]

  • 4. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [Abstract] [Full Text] [Related]

  • 5. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials.
    Hudson JI, Wohlreich MM, Kajdasz DK, Mallinckrodt CH, Watkin JG, Martynov OV.
    Hum Psychopharmacol; 2005 Jul; 20(5):327-41. PubMed ID: 15912562
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 11. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder.
    Raskin J, Wiltse CG, Dinkel JJ, Walker DJ, Desaiah D, Katona C.
    J Clin Psychopharmacol; 2008 Feb; 28(1):32-8. PubMed ID: 18204338
    [Abstract] [Full Text] [Related]

  • 12. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
    Lee P, Shu L, Xu X, Wang CY, Lee MS, Liu CY, Hong JP, Ruschel S, Raskin J, Colman SA, Harrison GA.
    Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
    [Abstract] [Full Text] [Related]

  • 13. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
    Mallinckrodt CH, Watkin JG, Liu C, Wohlreich MM, Raskin J.
    BMC Psychiatry; 2005 Jan 04; 5():1. PubMed ID: 15631624
    [Abstract] [Full Text] [Related]

  • 14. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
    Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ.
    Arthritis Rheum; 2004 Sep 04; 50(9):2974-84. PubMed ID: 15457467
    [Abstract] [Full Text] [Related]

  • 15. Management of depression relapse: re-initiation of duloxetine treatment or dose increase.
    Fava M, Detke MJ, Balestrieri M, Wang F, Raskin J, Perahia D.
    J Psychiatr Res; 2006 Jun 04; 40(4):328-36. PubMed ID: 16678205
    [Abstract] [Full Text] [Related]

  • 16. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
    Gaynor PJ, Gopal M, Zheng W, Martinez JM, Robinson MJ, Marangell LB.
    Curr Med Res Opin; 2011 Oct 04; 27(10):1849-58. PubMed ID: 21838411
    [Abstract] [Full Text] [Related]

  • 17. A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia.
    Chappell AS, Littlejohn G, Kajdasz DK, Scheinberg M, D'Souza DN, Moldofsky H.
    Clin J Pain; 2009 Jun 04; 25(5):365-75. PubMed ID: 19454869
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
    Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, Rickels K, Raskin J.
    Depress Anxiety; 2008 Jun 04; 25(3):182-9. PubMed ID: 17311303
    [Abstract] [Full Text] [Related]

  • 19. The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder.
    Arnold LM, Meyers AL, Sunderajan P, Montano CB, Kass E, Trivedi M, Wohlreich MM.
    Ann Clin Psychiatry; 2008 Jun 04; 20(4):187-93. PubMed ID: 19034749
    [Abstract] [Full Text] [Related]

  • 20. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
    Cowen PJ, Ogilvie AD, Gama J.
    Curr Med Res Opin; 2005 Mar 04; 21(3):345-56. PubMed ID: 15811202
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 93.